RxDoctor Payments Data

Mary Edwards, APRN

Family · Kitty Hawk, NCNPI 1437579083

Payments from drug & device makers

$1,580in general payments, 2019–2025

Across 97 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$805
  • Novo Nordisk$205
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$187
  • Novartis$112
  • Viiv Healthcare Company$66
  • Abbott$31
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$1,580100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,580 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,746
Medicare patients
46
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin95$129,079
OzempicSemaglutide71$105,365
EliquisApixaban41$44,103
TrulicityDulaglutide32$41,871
JanuviaSitagliptin Phosphate35$36,549
MounjaroTirzepatide25$34,290
RybelsusSemaglutide14$32,684
LinzessLinaclotide34$29,488
Synjardy XrEmpagliflozin/Metformin Hcl15$26,663
Breo ElliptaFluticasone/Vilanterol27$20,987
VraylarCariprazine Hcl15$20,376
ZenpepLipase/Protease/Amylase12$17,536
EntrestoSacubitril/Valsartan12$17,154
FarxigaDapagliflozin Propanediol11$16,159
Spiriva HandihalerTiotropium Bromide13$6,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$205$138,04985 claims
Lilly USA, LLCTrulicity, Mounjaro$24$76,16157 claims
AbbVieLinzess, Vraylar$805$49,86449 claims
PfizerEliquis$23$44,10341 claims
NovartisEntresto$112$17,15412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.

Other family in Kitty Hawk

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →